Management of aromatase inhibitor-associated bone loss (AIBL) in women with breast cancer
Osteoporosis and associated disorders
Materials
CLOSING THE CARE GAP: BARRIERS AND SOLUTIONS FOR GLOBAL ACCESS TO OSTEOPOROSIS MANAGEMENT
Date: November 2025 Speaker: Prof. Peyman Hadji
KEY LEARNING OBJECTIVES OF THIS WEBINAR INCLUDE:
- Understanding the pathophysiology and clinical impact of aromatase inhibitor-associated bone loss (AIBL) in women receiving adjuvant endocrine therapy for hormone-sensitive breast cancer.
- Reviewing current evidence-based guidelines for assessing fracture risk and monitoring bone health in patients receiving aromatase inhibitor therapy.
- IExamining new insights on how bone-protective therapies may influence breast cancer outcomes